GenSight Biologics S A : successfully raises €25 million in an oversubscribed private placement with US and European institutional investors
10/22/2020 | 01:15am EDT
The following information is not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the 'United States'), Canada, Japan or Australia, and does not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any securities in the United States, Canada, Japan or Australia. Any offers described on the website are not being made and will not be made directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or any facility of a national securities exchange of, the United States. All persons residing outside of the United States, Canada, Japan and Australia who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition or sale of securities by them. GenSight Biologics S.A. assumes no responsibility if there is a violation of applicable law and regulations by any person.
I certify that I am not a resident of or physically present in the United States, Canada, Japan or Australia.
I have read and understood the foregoing, and hereby make the certifications above and agree to comply with all of the above restrictions:
Gensight Biologics SA published this content on 22 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2020 05:14:05 UTC